Tetradecylthioacetic acid
CAS No. 2921-20-2
Tetradecylthioacetic acid( —— )
Catalog No. M28915 CAS No. 2921-20-2
Tetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 41 | In Stock |
|
| 5MG | 37 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 107 | In Stock |
|
| 50MG | 166 | In Stock |
|
| 100MG | 259 | In Stock |
|
| 200MG | 389 | In Stock |
|
| 500MG | 634 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTetradecylthioacetic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionTetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα.
-
DescriptionTetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα.(In Vivo):Mice receiving HFD supplemented with 0.75% (w/w) TTA had significantly lower body weights compared to mice fed the diet without TTA. Plasma triacylglycerol (TAG) was reduced 3-fold with TTA treatment, concurrent with increase in liver TAG. Total cholesterol was unchanged in plasma and liver. However, TTA promoted a shift in the plasma lipoprotein fractions with an increase in larger HDL particles. Histological analysis of the small intestine revealed a reduced size of lipid droplets in enterocytes of TTA treated mice, accompanied by increased mRNA expression of fatty acid transporter genes. Expression of the cholesterol efflux pump Abca1 was induced in the small intestine, but not in the liver. Scd1 displayed markedly increased mRNA and protein expression in the intestine of the TTA group.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2921-20-2
-
Formula Weight288.49
-
Molecular FormulaC16H32O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 2 mg/mL (6.93 mM)
-
SMILESCCCCCCCCCCCCCCSCC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.EUBULUS BIOTHERAPEUTICS - WO2021/183702, 2021, A1.
molnova catalog
related products
-
GFT505
GFT505 (Elafibranor) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
-
Bocidelpar
Bocidelpar is a modulator of PPARδ with an EC50 of 7.80 nM and improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy muscle cells.
-
JW55
JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively.
Cart
sales@molnova.com